Neurizon Therapeutics Limited has released a press release.
Canadian-based specialists to reformulate monepantel
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- New European patent granted for non-cancer applications
- PharmAust secures core patent in Japan
- Phase II trial prelim results demonstrate clinical benefit
- New patent granted for non-cancer applications
- PharmAust secures core China patent
Later from Neurizon Therapeutics
- Epichem reports record $3m revenues & expands laboratory
- PharmAust Shareholders Update
- Appendix 4E & Full Year Statutory Accounts 2017
- PharmAust & Nihon Nohyaku Japan Enter Assignment Agreement
- PharmAust secures core Europe patent
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics